$ESPR
Esperion Therapeutics, Inc. Stock $espr

$espr Overview Financials Valuation SEC Filings Company Website

2020 Q3 Form 10-Q Financial Statement

#000162828020015284 Filed on November 02, 2020

Income Statement

Concept	2020 Q3	2019 Q4	2019 Q3
Revenue	$3.833M	$982.0K	$981.0K
YoY Change	290.72%
Cost Of Revenue	$300.0K
YoY Change
Gross Profit	$3.600M
YoY Change
Gross Profit Margin	93.92%
Selling, General & Admin	$48.83M	$21.70M	$18.47M
YoY Change	164.38%	93.75%	105.2%
% of Gross Profit	1356.28%
Research & Development	$35.28M	$38.23M	$48.28M
YoY Change	-26.92%	-22.72%	16.2%
% of Gross Profit	980.08%
Depreciation & Amortization	$170.0K	$100.0K	$90.00K
YoY Change	88.89%	25.0%	28.57%
% of Gross Profit	4.72%
Operating Expenses	$84.38M	$59.95M	$66.75M
YoY Change	26.42%	-1.16%	32.01%
Operating Profit	-$80.55M	-$58.96M	-$65.77M
YoY Change	22.48%	-2.78%	30.07%
Interest Expense	$4.928M	$4.124M	$3.996M
YoY Change	23.32%		566.0%
% of Operating Profit
Other Income/Expense, Net	$42.00K	$1.142M	$1.387M
YoY Change	-96.97%	90.33%	113.06%
Pretax Income	-$85.40M	-$61.90M	-$68.40M
YoY Change	24.85%	3.17%	37.07%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$85.44M	-$61.95M	-$68.38M
YoY Change	24.95%	3.18%	37.0%
Net Earnings / Revenue	-2228.99%	-6308.15%	-6970.13%
Basic Earnings Per Share	-$3.07	-$2.26	-$2.52
Diluted Earnings Per Share	-$3.07	-$2.26	-$2.52
COMMON SHARES
Basic Shares Outstanding	27.83M shares	27.37M shares	27.17M shares
Diluted Shares Outstanding	27.83M shares	27.37M shares	27.17M shares

Balance Sheet

Concept	2020 Q3	2019 Q4	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$215.7M	$200.8M	$243.9M
YoY Change	-11.53%	47.61%	53.18%
Cash & Equivalents	$215.7M	$166.1M	$212.0M
Short-Term Investments	$0.00	$34.65M	$31.88M
Other Short-Term Assets	$18.00M	$10.90M	$9.600M
YoY Change	87.5%	65.15%	6.67%
Inventory	$9.061M	$0.00
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$242.8M	$211.7M	$253.5M
YoY Change	-4.2%	48.43%	50.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.408M	$1.145M	$958.0K
YoY Change	46.97%	120.19%	59.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$0.00
YoY Change			-100.0%
Other Assets	$56.00K	$56.00K
YoY Change
Total Long-Term Assets	$8.166M	$2.733M	$1.810M
YoY Change	351.16%	233.7%	-68.79%
TOTAL ASSETS
Total Short-Term Assets	$242.8M	$211.7M	$253.5M
Total Long-Term Assets	$8.166M	$2.733M	$1.810M
Total Assets	$251.0M	$214.4M	$255.3M
YoY Change	-1.68%	49.49%	46.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.58M	$28.86M	$23.74M
YoY Change	-25.92%	-35.72%	27.61%
Accrued Expenses	$45.80M	$29.80M	$31.20M
YoY Change	46.79%	53.61%	31.65%
Deferred Revenue	$1.662M	$2.152M	$2.618M
YoY Change	-36.52%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$75.95M	$66.08M	$57.52M
YoY Change	32.04%	2.72%	35.98%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.710M	$0.00	$129.2M
YoY Change	-98.68%
Total Long-Term Liabilities	$1.710M	$0.00	$129.2M
YoY Change	-98.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$75.95M	$66.08M	$57.52M
Total Long-Term Liabilities	$1.710M	$0.00	$129.2M
Total Liabilities	$242.0M	$194.5M	$186.8M
YoY Change	29.58%	202.33%	341.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$734.3M	-$695.3M	-$633.3M
YoY Change	15.95%	16.25%
Common Stock	$28.00K	$27.00K	$27.00K
YoY Change	3.7%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$0.00
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.960M	$19.95M	$68.51M
YoY Change
Total Liabilities & Shareholders Equity	$251.0M	$214.4M	$255.3M
YoY Change	-1.68%	49.49%	46.71%

Cashflow Statement

Concept	2020 Q3	2019 Q4	2019 Q3
OPERATING ACTIVITIES
Net Income	-$85.44M	-$61.95M	-$68.38M
YoY Change	24.95%	3.18%	37.0%
Depreciation, Depletion And Amortization	$170.0K	$100.0K	$90.00K
YoY Change	88.89%	25.0%	28.57%
Cash From Operating Activities	-$86.67M	-$49.99M	-$58.03M
YoY Change	49.35%	74.24%	54.62%
INVESTING ACTIVITIES
Capital Expenditures	$90.00K	-$170.0K	-$360.0K
YoY Change	-125.0%	70.0%	620.0%
Acquisitions
YoY Change
Other Investing Activities	$2.250M	-$2.700M	-$4.960M
YoY Change	-145.36%	-106.98%	-112.38%
Cash From Investing Activities	$2.330M	-$2.870M	-$5.310M
YoY Change	-143.88%	-107.44%	-113.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.600M	7.020M	970.0K
YoY Change	64.95%	1964.71%	-846.15%
NET CHANGE
Cash From Operating Activities	-86.67M	-49.99M	-58.03M
Cash From Investing Activities	2.330M	-2.870M	-5.310M
Cash From Financing Activities	1.600M	7.020M	970.0K
Net Change In Cash	-82.74M	-45.84M	-62.37M
YoY Change	32.66%	-548.53%	-2731.65%
FREE CASH FLOW
Cash From Operating Activities	-$86.67M	-$49.99M	-$58.03M
Capital Expenditures	$90.00K	-$170.0K	-$360.0K
Free Cash Flow	-$86.76M	-$49.82M	-$57.67M
YoY Change	50.44%	74.26%	53.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001434868
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35986
	dei	Entity Registrant Name EntityRegistrantName	Esperion Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1870780
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3891 Ranchero Drive, Suite 150
	dei	Entity Address City Or Town EntityAddressCityOrTown	Ann Arbor
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MI
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	48108
	dei	City Area Code CityAreaCode	734
	dei	Local Phone Number LocalPhoneNumber	887-3903
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	ESPR
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27876626	shares
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	215748000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	166130000	USD
CY2020Q3	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	928000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	34651000	USD
CY2020Q3	espr	Prepaid Clinical Development Costs Current PrepaidClinicalDevelopmentCostsCurrent	1110000	USD
CY2019Q4	espr	Prepaid Clinical Development Costs Current PrepaidClinicalDevelopmentCostsCurrent	6081000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	9061000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16884000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3924000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	242803000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	211714000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1408000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1145000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6702000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1532000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	56000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	56000	USD
CY2020Q3	us-gaap	Assets Assets	250969000	USD
CY2019Q4	us-gaap	Assets Assets	214447000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	17584000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	28856000	USD
CY2020Q3	espr	Accrued Clinical Development Costs Current AccruedClinicalDevelopmentCostsCurrent	21686000	USD
CY2019Q4	espr	Accrued Clinical Development Costs Current AccruedClinicalDevelopmentCostsCurrent	17511000	USD
CY2020Q3	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	21458000	USD
CY2019Q4	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	11871000	USD
CY2020Q3	espr	Revenue Interest Liability Current RevenueInterestLiabilityCurrent	10926000	USD
CY2019Q4	espr	Revenue Interest Liability Current RevenueInterestLiabilityCurrent	5236000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1662000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2152000	USD
CY2020Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2631000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	454000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	75947000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	66080000	USD
CY2020Q3	espr	Revenue Interest Liability Noncurrent RevenueInterestLiabilityNoncurrent	160247000	USD
CY2019Q4	espr	Revenue Interest Liability Noncurrent RevenueInterestLiabilityNoncurrent	127308000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4105000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1109000	USD
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1710000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2020Q3	us-gaap	Liabilities Liabilities	242009000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	194497000	USD
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27856298	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27856298	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27497911	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27497911	shares
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	28000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	27000	USD
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	743273000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	715166000	USD
CY2020Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	23000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-734341000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-695266000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	8960000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	19950000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	250969000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	214447000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3833000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	981000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	217909000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	147382000	USD
CY2020Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	275000	USD
CY2019Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	0	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	704000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	0	USD
CY2020Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	35283000	USD
CY2019Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	48281000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	104972000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	137377000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	48826000	USD
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18468000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	138060000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	44142000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	84384000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	66749000	USD
	us-gaap	Operating Expenses OperatingExpenses	243736000	USD
	us-gaap	Operating Expenses OperatingExpenses	181519000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-25827000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-80551000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-65768000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	4928000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-34137000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	3996000	USD
	us-gaap	Interest Expense InterestExpense	13739000	USD
	us-gaap	Interest Expense InterestExpense	3996000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	42000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1387000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	491000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2914000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-85437000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-68377000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-39075000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-35219000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.07
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.52
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.41
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.30
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	208000	USD
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27830281	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27171769	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27672325	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26995661	shares
CY2020Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2019Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	27000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-23000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	330000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-85437000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-68350000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39098000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34889000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	79118000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1669000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6636000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	87379000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	175010000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1887000	USD
CY2019Q2	espr	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	0	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6563000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	95000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-54221000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	129334000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1201000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6327000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	27000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-68377000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	68512000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	19950000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1014000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7053000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-14000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-78249000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-50246000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3738000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7395000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-9000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	124611000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	85489000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1644000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7264000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-85437000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	8960000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-39075000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-35219000	USD
	us-gaap	Depreciation Depreciation	387000	USD
	us-gaap	Depreciation Depreciation	218000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	97000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	140000	USD
	espr	Non Cash Interest Expense Related To Revenue Interest Liability NonCashInterestExpenseRelatedToRevenueInterestLiability	13739000	USD
	espr	Non Cash Interest Expense Related To Revenue Interest Liability NonCashInterestExpenseRelatedToRevenueInterestLiability	3996000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	21712000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	19526000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7989000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1802000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-490000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2618000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9061000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1710000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-11326000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-21158000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	13863000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	11614000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16627000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20347000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	4420000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	26630000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	39145000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	94510000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	693000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	781000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	34032000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	67099000	USD
	espr	Proceeds From Revenue Interest Purchase Agreement Net Of Issuance Costs ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts	25000000	USD
	espr	Proceeds From Revenue Interest Purchase Agreement Net Of Issuance Costs ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts	124424000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6395000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4757000	USD
	espr	Payments From Revenue Interest Purchase Agreement PaymentsFromRevenueInterestPurchaseAgreement	110000	USD
	espr	Payments From Revenue Interest Purchase Agreement PaymentsFromRevenueInterestPurchaseAgreement	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	31285000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	129181000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	48690000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	175933000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	167058000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36973000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	215748000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	212906000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	148000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	74000	USD
	espr	Non Cash Right Of Use Asset NonCashRightOfUseAsset	3000	USD
	espr	Non Cash Right Of Use Asset NonCashRightOfUseAsset	31000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of September 30, 2020, ten customers accounted for all of the Company's net trade receivables.</span></div>
	espr	Number Of Sources Of Revenue NumberOfSourcesOfRevenue	2	revenue_source
CY2020Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	206147000	USD
CY2020Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4103000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0	USD
CY2020Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4541000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	0	USD
CY2020Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	417000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	0	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	9061000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	206147000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	62589000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	23000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	62612000	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2020Q3	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	0	USD
CY2020Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3344000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	211000	USD
CY2020Q3	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	21458000	USD
CY2019Q4	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	11871000	USD
CY2019Q4	espr	Revenue Interest Liability RevenueInterestLiability	132544000	USD
	espr	Revenue Interest Liability Increase For Funding Received RevenueInterestLiabilityIncreaseForFundingReceived	25000000	USD
	espr	Payments From Revenue Interest Purchase Agreement PaymentsFromRevenueInterestPurchaseAgreement	110000	USD
CY2020Q3	espr	Revenue Interest Liability RevenueInterestLiability	171173000	USD
CY2020Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12156000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7818000	USD
CY2020Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5958000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3842000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4677929	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	39.31
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M25D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	109054000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	234940	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	61.14
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	213484	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	55.55
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	270735	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	23.62
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4428650	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	40.65
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y10M2D
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	38247000	USD
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4428650	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	40.65
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y10M2D
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	38247000	USD
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3274100	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	36.40
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y3D
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	36798000	USD
	espr	Operating Lease Increase Decrease In Right Of Use Assets OperatingLeaseIncreaseDecreaseInRightOfUseAssets	5200000	USD
	espr	Operating Lease Increase Decrease In Operating Lease Liabilities OperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilities	5200000	USD
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	700000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	1500000	USD
CY2020Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	700000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	1500000	USD
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	100000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	200000	USD
CY2019Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	100000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	200000	USD
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M6D
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.035
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	719000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2772000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2725000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	820000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	0	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7036000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	300000	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	6736000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4886260	shares
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4886260	shares
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5285466	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5285466	shares
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	215748000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	211978000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	166130000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36973000	USD
CY2020Q3	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2019Q3	us-gaap	Restricted Cash RestrictedCash	928000	USD
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	928000	USD
CY2018Q4	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	215748000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	212906000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	167058000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36973000	USD

Files In Submission

Name	View Source	Status
0001628280-20-015284-index-headers.html	Edgar Link	pending
0001628280-20-015284-index.html	Edgar Link	pending
0001628280-20-015284.txt	Edgar Link	pending
0001628280-20-015284-xbrl.zip	Edgar Link	pending
espr-20200930.htm	Edgar Link	pending
espr-20200930.xsd	Edgar Link	pending
espr-20200930_cal.xml	Edgar Link	unprocessable
espr-20200930_def.xml	Edgar Link	unprocessable
espr-20200930_htm.xml	Edgar Link	completed
espr-20200930_lab.xml	Edgar Link	unprocessable
espr-20200930_pre.xml	Edgar Link	unprocessable
espr-ex311x09302020.htm	Edgar Link	pending
espr-ex312x09302020.htm	Edgar Link	pending
espr-ex321x09302020.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ESPR
Esperion Therapeutics, Inc. Stock $espr

2020 Q3 Form 10-Q Financial Statement

#000162828020015284 Filed on November 02, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESPR Esperion Therapeutics, Inc. Stock $espr

2020 Q3 Form 10-Q Financial Statement

#000162828020015284 Filed on November 02, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESPR
Esperion Therapeutics, Inc. Stock $espr